×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLRB – cellectar biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLRB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
08:40 am
clrb
Cellectar Biosciences (CLRB) was upgraded by Maxim Group from "hold" to "buy". They now have a $10.00 price target on the stock.
Medium
Report
Cellectar Biosciences (CLRB) was upgraded by Maxim Group from "hold" to "buy". They now have a $10.00 price target on the stock.
3/4
10:17 am
clrb
Cellectar (CLRB) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Cellectar (CLRB) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/4
07:51 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates [Yahoo! Finance]
3/4
07:15 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
2/25
08:05 am
clrb
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Low
Report
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
2/17
08:05 am
clrb
Cellectar Biosciences Expands Global Intellectual Property Estate
High
Report
Cellectar Biosciences Expands Global Intellectual Property Estate
1/9
08:05 am
clrb
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Medium
Report
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
3/4/2026
07:15 am
clrb
cellectar biosciences, inc.
MISS
Report
8.2%
cellectar biosciences, inc.
11/13/2025
07:20 am
clrb
cellectar biosciences, inc.
BEAT
Report
-10.7%
cellectar biosciences, inc.
8/14/2025
07:19 am
clrb
cellectar biosciences, inc.
BEAT
Report
-1.8%
cellectar biosciences, inc.
5/13/2025
07:05 am
clrb
cellectar biosciences, inc.
BEAT
Report
-13.2%
cellectar biosciences, inc.
Date
Time
Symbol
Headline
Impact
3/4
07:24 am
clrb
Form 8-K Cellectar Biosciences, For: Mar 04
Medium
Report
Form 8-K Cellectar Biosciences, For: Mar 04
3/4
07:22 am
clrb
Form 10-K Cellectar Biosciences, For: Dec 31
Medium
Report
Form 10-K Cellectar Biosciences, For: Dec 31
2/13
04:44 pm
clrb
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Bleichroeder LP
Medium
Report
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Bleichroeder LP
2/10
03:23 pm
clrb
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Rosalind Advisors, Inc.
Low
Report
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Rosalind Advisors, Inc.
2/4
04:11 pm
clrb
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Hexstone Capital LLC
Medium
Report
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Hexstone Capital LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
Cellectar Biosciences Inc (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
17.5%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
TOP News Decliners
7/9
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
-26.9%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: